|1.||Beijnen, J H: 2 articles (04/2010 - 06/2007)|
|2.||Witteveen, P O: 2 articles (04/2010 - 06/2007)|
|3.||Schellens, J H M: 2 articles (04/2010 - 06/2007)|
|4.||Voest, E E: 2 articles (04/2010 - 06/2007)|
|5.||Schot, M: 2 articles (04/2010 - 06/2007)|
|6.||Nazarian, K B: 1 article (03/2012)|
|7.||Varzhabetian, L R: 1 article (03/2012)|
|8.||Glazachev, D V: 1 article (03/2012)|
|9.||Tomillero, A: 1 article (12/2010)|
|10.||Moral, M A: 1 article (12/2010)|
01/01/2001 - "Because of its synthetic nature, its oral applicability, its potent in vitro and in vivo antitumoral activity, its efficacy against multidrug-resistant tumors, and the lack of neurotoxicity, D-24851 may have significant potential for the treatment of various malignancies."
04/01/2010 - "The purpose of this phase I study was to determine the maximum tolerated dose (MTD) as well as the dose limiting toxicity (DLT), the pharmacokinetics, safety and tolerability of orally administered indibulin as capsule formulation in patients with advanced solid tumors. "
04/01/2010 - "Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors."
01/01/2009 - "The observed broad antitumor activity of indibulin and the lack of central and peripheral nervous system toxicity in preclinical studies make it a promising candidate for development as a cancer treatment. "
06/01/2007 - "The primary study objectives were to determine the impact of fasted and fed condition on pharmacokinetic parameters, as well as the maximum tolerated dose of the oral drinking solution of indibulin administered once daily for 14 days every 3 weeks in patients with solid tumors. "
|2.||Pathologic Constriction (Stenosis)
03/01/2005 - "The results of this study make D-24851 even more promising as a therapeutic agent, especially because many malignant gliomas have a heterogeneous p53 status."
03/01/2005 - "Our results indicated that D-24851 effectively induces apoptosis through Bcl-2 phosphorylation and Bax translocation in human malignant glioma cells in a p53-independent manner. "
03/01/2005 - "D-24851 substantially inhibited the proliferation of the four glioma cell lines tested in a dose- and time-dependent manner. "
03/01/2005 - "Microtubule inhibitor D-24851 induces p53-independent apoptotic cell death in malignant glioma cells through Bcl-2 phosphorylation and Bax translocation."
03/01/2005 - "Here, we investigated the in vitro effect of D-24851 on tumor growth and the apoptosis mechanism in human malignant glioma cells. "
|5.||Sarcoma (Soft Tissue Sarcoma)
|3.||17-alpha-Hydroxyprogesterone (17 Hydroxyprogesterone)